We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Rubius Therapeutics Inc | NASDAQ:RUBY | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.083 | 0.0888 | 0.0894 | 0 | 01:00:00 |
|
Delaware
(State or other jurisdiction of
incorporation or organization) |
| |
46-2688109
(I.R.S. Employer
Identification Number) |
|
| Large accelerated filer ☒ | | |
Accelerated filer ☐
|
| |
Non-accelerated filer ☐
|
| |
Smaller reporting company ☐
Emerging growth company ☐ |
|
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 3 | | | |
| | | | 5 | | | |
| | | | 6 | | | |
| | | | 7 | | | |
| | | | 8 | | | |
| | | | 13 | | | |
| | | | 19 | | | |
| | | | 20 | | | |
| | | | 23 | | | |
| | | | 26 | | | |
| | | | 26 | | | |
| | | | 26 | | | |
| | | | 27 | | |
|
SEC registration fee
|
| | | $ | 23,175 | | |
|
FINRA filing fee
|
| | | | * | | |
|
Legal fees and expenses
|
| | | | * | | |
|
Accounting fees and expenses
|
| | | | * | | |
|
Printing fees and expenses
|
| | | | * | | |
|
Transfer agent and trustee fees
|
| | | | * | | |
|
Miscellaneous
|
| | | | * | | |
|
Total
|
| | | $ | * | | |
Exhibit
No. |
| |
Description
|
| |||
| | 1.1* | | | | Form of Underwriting Agreement | |
| | 3.1 | | | | Amended and Restated Certificate of Incorporation of the Registrant (Incorporated by reference to Exhibit 3.1 to the Registrant’s Form 8-K (File No. 001-38586) filed with the SEC on July 23, 2018) | |
| | 3.2 | | | | | |
| | 4.1 | | | | | |
| | 4.2 | | | | Second Amended and Restated Investors’ Rights Agreement among the Registrant and certain of its stockholders, dated February 23, 2018 (Incorporated by reference to Exhibit 4.2 to the Registrant’s Registration Statement on Form S-1 (File No. 333-225840) filed on June 22, 2018) | |
| | 4.3 | | | | | |
| | 4.4 | | | | | |
| | 4.5* | | | | Form of Certificate of Designations | |
| | 4.6* | | | | Form of Warrant Agreement | |
| | 4.7* | | | | Form of Unit Agreement and Unit Certificate | |
| | 4.8* | | | | Form of Preferred Stock Certificate | |
| | 5.1 | | | | | |
| | 23.1 | | | | | |
| | 23.2 | | | | | |
| | 24.1 | | | | | |
| | 25.1** | | | |
Form T-1 Statement of Eligibility of Trustee for Senior Indenture under the Trust Indenture Act of
1939 |
|
| | 25.2** | | | | Form T-1 Statement of Eligibility of Trustee for Subordinated Indenture under the Trust Indenture Act of 1939 | |
| | 107 | | | | |
| | | | RUBIUS THERAPEUTICS, INC. | | |||
| | | | By: | | |
/s/ Pablo J. Cagnoni
Pablo J. Cagnoni
Chief Executive Officer |
|
|
Signature
|
| |
Title
|
| |
Date
|
|
|
/s/ Pablo J. Cagnoni
Pablo J. Cagnoni, M.D.
|
| | Chief Executive Officer, Director (Principal Executive Officer) | | |
June 8, 2022
|
|
|
/s/ Jose Carmona
Jose Carmona
|
| | Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) | | |
June 8, 2022
|
|
|
/s/ Noubar B. Afeyan
Noubar B. Afeyan, Ph.D.
|
| | Chairman of the Board of Directors | | |
June 8, 2022
|
|
|
/s/ David R. Epstein
David R. Epstein
|
| | Director | | |
June 8, 2022
|
|
|
/s/ Francis Cuss
Francis Cuss, M.B., B.Chir, FRCP
|
| | Director | | |
June 8, 2022
|
|
|
/s/ Natalie Holles
Natalie Holles
|
| | Director | | |
June 8, 2022
|
|
|
/s/ Anne Prener
Anne Prener, M.D., Ph.D.
|
| | Director | | |
June 8, 2022
|
|
|
Signature
|
| |
Title
|
| |
Date
|
|
|
/s/ Michael Rosenblatt
Michael Rosenblatt, M.D.
|
| | Director | | |
June 8, 2022
|
|
|
/s/ Catherine A. Sohn
Catherine A. Sohn, Pharm.D.
|
| | Director | | |
June 8, 2022
|
|
|
/s/ Jonathan R. Symonds
Jonathan R. Symonds, CBE
|
| | Director | | |
June 8, 2022
|
|
1 Year Rubius Therapeutics Chart |
1 Month Rubius Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions